Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone, and welcome to the Champions Oncology fourth quarter fiscal year 2026 earnings call. At this time, all participants are placed on a listen-only mode. If you have any questions or comments during the presentation, you may press star 1 to enter the question queue at any time, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to hand the floor over to your host, Rob Brainin, CEO, Thank you. Good afternoon, and thank you for joining our fiscal 2026 year-end earnings call. I'm Ron Brainin, CEO of Champions Oncology, and I'm joined today by our CFO, David Miller. Before we begin, I'll remind everyone that today's remarks may include forward-looking statements. Actual results may differ materially, and you can find more information in our filings with the SEC. I'd like to begin by referring back to what I said shortly after second I said then that we will build on the progress the company has made over the recent years, stay focused on positive adjusted EBITDA for the year, and at the same time keep investing in our two growth vectors, data and Corellia, with returns on those investments coming in later quarters and years, as well as continuing to invest in our TOS business, especially around growth areas like the radio ligand platform. I'm pleased to say our execution against that plan held up well. In fiscal 2026, we delivered record annual revenue and met our commitment to full-year positive adjusted EBITDA, including positive adjusted EBITDA in each of the four quarters on the zone, the first time that has happened since fiscal 2022, driven by real strength in our core services business. Our data business did not repeat its fiscal 2025 revenue, but the comparison is less telling than it looks, an...